Novo Nordisk, Wegovy
European Drug Agency Supports Novo Nordisk's Blockbuster Weight-Loss Drug Wegovy For Obesity-Related Heart Failure
Novo Nordisk's Wegovy label update receives a positive opinion from the EMA's CHMP, highlighting improvements in heart failure symptoms, physical limitations, and exercise function in patients with obesity-related HFpEF.
Ozempic maker Novo Nordisk (NVO) announced mixed results today for a phase 2 trial of an experimental weight loss pill that ...
Novo Nordisk and Eli Lilly are offering discounts to encourage more insurance coverage of the medicines, which carry price ...
China has started cracking down on unlicensed production and sale of medicines similar to Novo Nordisk A/S’s blockbuster ...
Weight-loss drugs like Ozempic are booming in popularity, but experts warn they aren't silver bullets for obesity.
One of the world’s largest drug manufacturers is suing a small east metro wellness center over the way it marketed and sold a ...
Many people are doing an end-run around their doctor's office, reaching out to potentially unreliable sources that promise to ...
Injectable prescription drugs that reduce appetite — like Ozempic, Saxenda and Mounjaro — have skyrocketed in popularity in ...
People taking the experimental drug amycretin were found to lose almost twice as much weight over a 12-week period as the ...
F ROM LOS ANGELES to London, weight-loss drugs such as Ozempic are reshaping culture as much as waistlines. Some ...
For people who pay out of pocket, Lilly recently introduced vials of its drug Zepbound that cost as little as 399 dollars a month. To compete, Novo Nordisk ramped up its rebating -- average Wegovy ...
Researchers found that patients with obesity had an average weight loss of 12.9% with semaglutide vs 5.6% with liraglutide ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback